Physician profile
M Bassel Atassi
NPI 1689876328
$9,913.06
in general payments reported to CMS, 2019-2025
46 companies · $83.99 in 2025
The $83.99 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,681 · 2020: $200 · 2021: $3,147 · 2022: $3,037 · 2023: $1,462 · 2024: $303 · 2025: $83.99.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,700 · Education: $149.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,700.08 |
| Education | $148.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $5,522.51 | 2019-2023 | Calquence, Enhertu |
| Genentech USA, INC. | $523.03 | 2019-2023 | Venclexta, Avastin, Tecentriq |
| Merck Sharp & Dohme LLC | $477.22 | 2019-2023 | Keytruda, Lynparza, Welireg |
| Pfizer INC. | $402.86 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $289.89 | 2019-2024 | Opdivo |
| Janssen Biotech, INC. | $265.68 | 2019-2025 | Talvey, Tecvayli, Darzalex |
| Gilead Sciences, INC. | $205.44 | 2021-2023 | Trodelvy |
| Takeda Pharmaceuticals U.S.A., INC. | $196.64 | 2019-2024 | Ninlaro, Alunbrig |
| Celgene Corporation | $192.11 | 2019-2023 | Reblozyl |
| Lilly USA, LLC | $123.00 | 2019-2023 | Retevmo, Jaypirca, Verzenio |
| Seagen INC. | $119.55 | 2019-2023 | Padcev, Tukysa |
| Boston Scientific Corporation | $118.57 | 2024 | Watchman Flx |
| Novartis Pharmaceuticals Corporation | $116.04 | 2019-2023 | |
| Amgen INC. | $105.53 | 2019-2023 | Lumakras |
| Morphosys, US INC. | $102.30 | 2022 |
Show all 44 companies
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw M Bassel Atassi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.